Daré Bioscience, Inc. (NASDAQ:DARE) Sees Significant Increase in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 246,900 shares, an increase of 5.1% from the March 31st total of 235,000 shares. Based on an average trading volume of 438,000 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

Several analysts have weighed in on DARE shares. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Daré Bioscience in a research report on Wednesday. Dawson James cut Daré Bioscience from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 30th. Finally, Brookline Capital Management cut Daré Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently bought a new stake in Daré Bioscience stock. Armistice Capital LLC acquired a new position in Daré Bioscience, Inc. (NASDAQ:DARE) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned about 7.37% of Daré Bioscience as of its most recent SEC filing. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Stock Up 7.3 %

Shares of DARE opened at $0.33 on Thursday. The business’s 50 day moving average price is $0.45 and its 200-day moving average price is $0.39. Daré Bioscience has a 52 week low of $0.27 and a 52 week high of $1.06. The stock has a market cap of $33.18 million, a P/E ratio of -0.97 and a beta of 1.16.

Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The company had revenue of $1.81 million during the quarter, compared to the consensus estimate of $2.17 million. On average, equities analysts anticipate that Daré Bioscience will post -0.22 EPS for the current year.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.